-
Article
First-in-human imaging using [11C]MDTC: a radiotracer targeting the cannabinoid receptor type 2
We report findings from the first-in-human study of [11C]MDTC, a radiotracer developed to image the cannabinoid receptor type 2 (CB2R) with positron emission tomography (PET).
-
Article
Correction to: Hetero-bivalent agents targeting FAP and PSMA
-
Article
Hetero-bivalent agents targeting FAP and PSMA
We developed a theranostic radiopharmaceutical that engages two key cell surface proteases, fibroblast activation protein alpha (FAP) and prostate-specific membrane antigen (PSMA), each frequently overexpresse...
-
Article
First-in-human neuroimaging of soluble epoxide hydrolase using [18F]FNDP PET
Soluble epoxide hydrolase (sEH) is an enzyme with putative effect on neuroinflammation through its influence on the homeostasis of polyunsaturated fatty acids and related byproducts. sEH is an enzyme that meta...
-
Article
Open AccessPET imaging of soluble epoxide hydrolase in non-human primate brain with [18F]FNDP
Soluble epoxide hydrolase (sEH) is a promising candidate positron emission tomography (PET) imaging biomarker altered in various disorders, including vascular cognitive impairment (VCI), Alzheimer’s disease (A...
-
Article
177Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy
To develop a prostate-specific membrane antigen (PSMA)-targeted radiotherapeutic for metastatic castration-resistant prostate cancer (mCRPC) with optimized efficacy and minimized toxicity employing the β-parti...